RSS-Feed abonnieren

DOI: 10.1055/s-0043-1761261
Laboratory Workup of Hypereosinophilia
Authors
Funding None.

Abstract
Hypereosinophilia (HE) can be caused by a wide variety of non-hematologic (secondary or reactive) and hematologic (primary, clonal) disorders. Diagnosing hypereosinophilia/hypereosinophilic syndrome (HE/HES) is challenging due to the complex nature of disease manifestations and numerous underlying etiologies. Knowing that only rare cases are clonal, it is wise to rule out reactive conditions and proceed with molecular and other advanced tools. The exclusion of secondary causes needs a detailed clinical evaluation followed by a wide range of serological and imaging investigations. Once reactive eosinophilia has been ruled out, the diagnosis of primary HE/HES is made using a combination of morphologic examination of the blood and bone marrow, conventional cytogenetics, fluorescent in situ hybridization, flow-cytometry, and T-cell clonality evaluation to look for histopathologic or clonal evidence of an underlying hematological disorder. The accurate diagnosis of clonal eosinophilia-causing myeloid and lymphoid neoplasms and the identification of numerous gene rearrangements significantly enhance patient outcomes, because a proportion of these patients (such as PDGFRA and PDGFRB rearrangements) responds well to tyrosine kinase inhibitors. Considering the complex etiopathologies, the cost of testing, and the time involved, the workup needs to be tailored according to the urgency of the situation and the resources available. In urgent situations with organ damage, it is crucial to initiate appropriate management without waiting for the results of investigations. In contrast, in a resource-limited situation, it is acceptable to employ step-by-step rather than comprehensive testing to rule out the most common causes first. Here, we discuss various laboratory investigations employed in diagnosing HE/HES, highlighting their importance in different situations.
Keywords
hypereosinophilia - hypereosinophilic syndrome - mastocytosis - tyrosine kinase domain fusions - myelodysplastic syndromes - myeloproliferative neoplasmsAuthors' Contributions
D.S. wrote initial manuscript; S.S. revised and approved the final manuscript.
Publikationsverlauf
Artikel online veröffentlicht:
17. April 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Valent P, Klion AD, Horny HP. et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012; 130 (03) 607-612.e9
- 2 McNagny K, Graf T. Making eosinophils through subtle shifts in transcription factor expression. J Exp Med 2002; 195 (11) F43-F47
- 3 Leru PM. Eosinophilic disorders: evaluation of current classification and diagnostic criteria, proposal of a practical diagnostic algorithm. Clin Transl Allergy 2019; 9: 36
- 4 Kato M, Kephart GM, Talley NJ. et al. Eosinophil infiltration and degranulation in normal human tissue. Anat Rec 1998; 252 (03) 418-425
- 5 Simon HU, Rothenberg ME, Bochner BS. et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 2010; 126 (01) 45-49
- 6 Shomali W, Gotlib J. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 2022; 97 (01) 129-148
- 7 Butt NM, Lambert J, Ali S. et al; British Committee for Standards in Haematology. Guideline for the investigation and management of eosinophilia. Br J Haematol 2017; 176 (04) 553-572
- 8 Sreedharanunni S, Varma N, Sachdeva MUS. et al. The spectrum of hypereosinophilia and associated clonal disorders - a real-world data based on combined retrospective and prospective analysis from a tropical setting. Mediterr J Hematol Infect Dis 2018; 10 (01) e2018052
- 9 Banday AZ, Bhattarai D, Bhagat N, Sreedharanunni S, Khurana S, Suri D. Pediatric hypereosinophilia and toxoplasma: peregrination beyond facileness. J Family Med Prim Care 2021; 10 (09) 3511-3514
- 10 Navabi B, Upton JEM. Primary immunodeficiencies associated with eosinophilia. Allergy Asthma Clin Immunol 2016; 12: 27
- 11 Long H, Zhang G, Wang L, Lu Q. Eosinophilic skin diseases: a comprehensive review. Clin Rev Allergy Immunol 2016; 50 (02) 189-213
- 12 Vignesh P, Kishore J, Kumar A. et al. A young child with eosinophilia, rash, and multisystem illness: drug rash, eosinophilia, and systemic symptoms syndrome after receipt of fluoxetine. Pediatr Dermatol 2017; 34 (03) e120-e125
- 13 Musette P, Janela B. New insights into drug reaction with eosinophilia and systemic symptoms pathophysiology. Front Med (Lausanne) 2017; 4: 179
- 14 Kardaun SH, Sekula P, Valeyrie-Allanore L. et al; RegiSCAR study group. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013; 169 (05) 1071-1080
- 15 Zalewska E, Obołończyk Ł, Sworczak K. Hypereosinophilia in solid tumors-case report and clinical review. Front Oncol 2021; 11: 639395
- 16 Hu Z, Wang W, Thakral B. et al. Lymphocytic variant of hypereosinophilic syndrome: a report of seven cases from a single institution. Cytometry B Clin Cytom 2021; 100 (03) 352-360
- 17 Desmond A, Kilmer E, Cerny J, Nath R, Ramanathan M. Peripheral blood eosinophilia as a marker of chronic graft versus host disease (cGVHD). Biol Blood Marrow Transplant 2016; 22: S409
- 18 Takayasu S, Mizushiri S, Watanuki Y. et al. Eosinophil counts can be a predictive marker of immune checkpoint inhibitor-induced secondary adrenal insufficiency: a retrospective cohort study. Sci Rep 2022; 12 (01) 1294
- 19 Cecioni I, Fassio F, Gori S, Giudizi MG, Romagnani S, Almerigogna F. Eosinophilia in cholesterol atheroembolic disease. J Allergy Clin Immunol 2007; 120 (06) 1470-1471 , author reply 1471
- 20 Khoury P, Herold J, Alpaugh A. et al. Episodic angioedema with eosinophilia (Gleich syndrome) is a multilineage cell cycling disorder. Haematologica 2015; 100 (03) 300-307
- 21 Montgomery ND, Dunphy CH, Mooberry M. et al. Diagnostic complexities of eosinophilia. Arch Pathol Lab Med 2013; 137 (02) 259-269
- 22 Helbig G, Klion AD. Hypereosinophilic syndromes - an enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment. Blood Rev 2021; 49: 100809
- 23 Roufosse F, Cogan E, Goldman M. Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007; 27 (03) 389-413
- 24 Cools J, DeAngelo DJ, Gotlib J. et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348 (13) 1201-1214
- 25 Roche-Lestienne C, Lepers S, Soenen-Cornu V. et al. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 2005; 19 (05) 792-798
- 26 Wang SA. The diagnostic work-up of hypereosinophilia. Pathobiology 2019; 86 (01) 39-52
- 27 Roufosse F, Weller PF. Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol 2010; 126 (01) 39-44
- 28 Goasguen JE, Bennett JM, Bain BJ. et al; International Working Group on Morphology of MDS. The role of eosinophil morphology in distinguishing between reactive eosinophilia and eosinophilia as a feature of a myeloid neoplasm. Br J Haematol 2020; 191 (03) 497-504
- 29 Gauchan D, Joshi N, Gill AS. et al. Does an elevated serum vitamin B(12) level mask actual vitamin B(12) deficiency in myeloproliferative disorders?. Clin Lymphoma Myeloma Leuk 2012; 12 (04) 269-273
- 30 Sahu KK, Malhotra P, Khadwal A. et al. Hypereosinophilia in Acute Lymphoblastic Leukemia: Two Cases with Review of Literature. Indian J Hematol Blood Transfus 2015; 31 (04) 460-465
- 31 Khoury JD, Solary E, Abla O. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022; 36: 1703-1719
- 32 Kapatia G, Remani ASN, Naseem S, Parihar M, Sreedharanunni S. Myeloid neoplasm with t(8;22)(p11;q11): a mimicker of chronic myeloid leukaemia in blast crisis. Indian J Hematol Blood Transfus 2021; 37 (02) 334-336
- 33 Fournier B, Balducci E, Duployez N. et al. B-ALL With t(5;14)(q31;q32); IGH-IL3 rearrangement and eosinophilia: a comprehensive analysis of a peculiar IGH-rearranged B-ALL. Front Oncol 2019; 9: 1374
- 34 Sreedharanunni S, Sachdeva MUS, Sharma S. et al. Paratrabecular myelofibrosis and occult mastocytosis are strong morphological clues to suspect FIP1L1-PDGFRA translocation in hypereosinophilia. Indian J Hematol Blood Transfus 2020; 36 (02) 384-389
- 35 Bacher U, Schanz J, Braulke F, Haase D. Rare cytogenetic abnormalities in myelodysplastic syndromes. Mediterr J Hematol Infect Dis 2015; 7 (01) e2015034
- 36 Batanian JR, Slovak ML, Mohamed A, Dobin S, Luthardt FW, Keitges EA. Trisomy 15 is frequently observed as a minor clone in patients with Anemia/MDS/NHL and as a major clone in patients with AML. Cancer Genet Cytogenet 2000; 121 (02) 186-189
- 37 Sharma P, Rana S, Sreedharanunni S. et al. An evaluation of a fluorescence in situ hybridization strategy using air-dried blood and bone-marrow smears in the risk stratification of pediatric b-lineage acute lymphoblastic leukemia in resource-limited settings. J Pediatr Hematol Oncol 2021; 43 (04) e481-e485
- 38 Virk H, Rathore S, Anshu A. et al. Imatinib responsive erythrocytosis in a patient with FIP1L1:PDGFRA rearranged myeloid neoplasm with hypereosinophilia - Another manifestation of a stem cell neoplasm. Leuk Res 2022; 121: 106922
- 39 Olsson-Arvidsson L, Norberg A, Sjögren H, Johansson B. Frequent false-negative FIP1L1-PDGFRA FISH analyses of bone marrow samples from clonal eosinophilia at diagnosis. Br J Haematol 2020; 188 (05) e76-e79
- 40 Wang SA, Tam W, Tsai AG. et al. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Mod Pathol 2016; 29 (08) 854-864
- 41 Helbig G, Wieczorkiewicz A, Dziaczkowska-Suszek J, Majewski M, Kyrcz-Krzemien S. T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome. Haematologica 2009; 94 (09) 1236-1241
- 42 Morsia E, Reichard K, Pardanani A, Tefferi A, Gangat N. WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): a contemporary series from the Mayo Clinic. Am J Hematol 2020; 95 (07) E172-E174
- 43 Sreedharanunni S, Jamwal M, Balakrishnan A. et al. Chronic eosinophilic leukemia with recurrent STAT5B N642H mutation-an entity with features of myelodysplastic syndrome/ myeloproliferative neoplasm overlap. Leuk Res 2022; 112: 106753
- 44 Klion AD. How I treat hypereosinophilic syndromes. Blood 2015; 126 (09) 1069-1077
